168 related articles for article (PubMed ID: 20635186)
1. The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism.
Bovi T; Antonini A; Ottaviani S; Antonioli A; Cecchini MP; Di Francesco V; Bassetto MA; Zamboni M; Fiaschi A; Moretto G; Sbarbati A; Osculati F; Tinazzi M
J Neurol; 2010 Nov; 257(11):1882-9. PubMed ID: 20635186
[TBL] [Abstract][Full Text] [Related]
2. Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson's disease.
Oh YS; Kim JS; Hwang EJ; Lyoo CH
Parkinsonism Relat Disord; 2018 Nov; 56():47-51. PubMed ID: 29925486
[TBL] [Abstract][Full Text] [Related]
3. Olfactory dysfunction correlates with putaminal dopamine turnover in early de novo Parkinson's disease.
Löhle M; Wolz M; Beuthien-Baumann B; Oehme L; van den Hoff J; Kotzerke J; Reichmann H; Storch A
J Neural Transm (Vienna); 2020 Jan; 127(1):9-16. PubMed ID: 31863171
[TBL] [Abstract][Full Text] [Related]
4. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
[TBL] [Abstract][Full Text] [Related]
5. Nigrostriatal dopamine-independent resting-state functional networks in Parkinson's disease.
Ham JH; Cha J; Lee JJ; Baek GM; Sunwoo MK; Hong JY; Shin NY; Sohn YH; Lee JM; Lee PH
Neuroimage; 2015 Oct; 119():296-304. PubMed ID: 26143204
[TBL] [Abstract][Full Text] [Related]
6. Correlation between the availability of dopamine transporter and olfactory function in healthy subjects.
Pak K; Kim K; Lee MJ; Lee JM; Kim BS; Kim SJ; Kim IJ
Eur Radiol; 2018 Apr; 28(4):1756-1760. PubMed ID: 29164380
[TBL] [Abstract][Full Text] [Related]
7. Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease.
Bohnen NI; Gedela S; Kuwabara H; Constantine GM; Mathis CA; Studenski SA; Moore RY
J Neurol; 2007 Jan; 254(1):84-90. PubMed ID: 17508142
[TBL] [Abstract][Full Text] [Related]
8. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.
Stiasny-Kolster K; Doerr Y; Möller JC; Höffken H; Behr TM; Oertel WH; Mayer G
Brain; 2005 Jan; 128(Pt 1):126-37. PubMed ID: 15548552
[TBL] [Abstract][Full Text] [Related]
9. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.
Gerschlager W; Bencsits G; Pirker W; Bloem BR; Asenbaum S; Prayer D; Zijlmans JC; Hoffmann M; Brücke T
Mov Disord; 2002 May; 17(3):518-23. PubMed ID: 12112200
[TBL] [Abstract][Full Text] [Related]
10. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
[TBL] [Abstract][Full Text] [Related]
11. Early-onset drug-induced parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction.
Chung SJ; Yoo HS; Moon H; Oh JS; Kim JS; Park YH; Hong JY; Ye BS; Sohn YH; Lee PH
J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):169-174. PubMed ID: 28912301
[TBL] [Abstract][Full Text] [Related]
12. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
[TBL] [Abstract][Full Text] [Related]
13. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease.
Siepel FJ; Brønnick KS; Booij J; Ravina BM; Lebedev AV; Pereira JB; Grüner R; Aarsland D
Mov Disord; 2014 Dec; 29(14):1802-8. PubMed ID: 25284687
[TBL] [Abstract][Full Text] [Related]
14. Cognitive and olfactory deficits in Machado-Joseph disease: a dopamine transporter study.
Braga-Neto P; Felicio AC; Hoexter MQ; Pedroso JL; Dutra LA; Alessi H; Minett T; Santos-Galduroz RF; da Rocha AJ; Garcia LA; Bertolucci PH; Bressan RA; Barsottini OG
Parkinsonism Relat Disord; 2012 Aug; 18(7):854-8. PubMed ID: 22575233
[TBL] [Abstract][Full Text] [Related]
15. Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity.
Bohnen NI; Gedela S; Herath P; Constantine GM; Moore RY
Neurosci Lett; 2008 Dec; 447(1):12-6. PubMed ID: 18838108
[TBL] [Abstract][Full Text] [Related]
16. Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson's disease.
Nabizadeh F; Sodeifian F; Pirahesh K
Neurol Sci; 2022 Aug; 43(8):4745-4752. PubMed ID: 35508569
[TBL] [Abstract][Full Text] [Related]
17. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease.
Lorberboym M; Treves TA; Melamed E; Lampl Y; Hellmann M; Djaldetti R
Mov Disord; 2006 Apr; 21(4):510-4. PubMed ID: 16250023
[TBL] [Abstract][Full Text] [Related]
18. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.
Colloby SJ; Williams ED; Burn DJ; Lloyd JJ; McKeith IG; O'Brien JT
Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1176-85. PubMed ID: 15931516
[TBL] [Abstract][Full Text] [Related]
19. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
20. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
